Deregulation of c-Myc Confers Distinct Survival Requirements for Memory B Cells, Plasma Cells, and Their Progenitors

Sefat E. Khuda, William M. Loo, Siegfried Janz, Brian Van Ness and Loren D. Erickson

*J Immunol* 2008; 181:7537-7549; doi: 10.4049/jimmunol.181.11.7537
http://www.jimmunol.org/content/181/11/7537

**References**
This article cites 88 articles, 39 of which you can access for free at:
http://www.jimmunol.org/content/181/11/7537.full#ref-list-1

**Subscription**
Information about subscribing to The Journal of Immunology is online at:
http://jimmunol.org/subscription

**Permissions**
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Deregulation of c-Myc Confers Distinct Survival Requirements for Memory B Cells, Plasma Cells, and Their Progenitors

Sefat E. Khuda,* William M. Loo,* Siegfried Janz, † Brian Van Ness,‡ and Loren D. Erickson†‡

Deregulation of the e-Myc oncogene is tightly associated with human and murine plasma cell (PC) neoplasms. Through the analysis of Ag-specific B cell responses in mice where Myc is targeted to the IgH C\(\alpha\) locus, we show here that c-Myc dramatically impairs the primary and secondary Ab response. This impairment is differentiation stage specific, since germinal center B cell formation, affinity maturation, and class switch recombination were intact. Examination of PC viability revealed that c-Myc triggered apoptosis only upon final maturation when Ab is secreted and is resistant to the survival factor BAFF (B cell-activating factor belonging to the TNF family). In contrast, PC precursors (PC\(_{\text{pre}}\)) that ultimately give rise to mature PCs survived normally and vigorously expanded with BAFF signaling. We further show that c-Myc also facilitates the apoptosis of memory B cells. Thus, C\(\alpha\)-Myc controls both cellular arms of long-lived B cell immunity than previously anticipated. Only when deregulation of c-Myc was combined with enforced Bcl-x\(_L\) expression were mature PCs able to survive in response to BAFF. These data indicate that the survival requirements for tumor-susceptible PC\(_{\text{pre}}\) and PCs are distinct and that tumor progression likely develops as PC\(_{\text{pre}}\) transition to functional PCs when apoptotic pathways such as members of the Bcl-2 family are disabled. The Journal of Immunology, 2008, 181: 7537–7549.

Plasma cells (PC)\(^3\) represent a terminal stage of B cell differentiation whose function is to synthesize and secrete large amounts of Ag-specific Ab that provide the host with protective humoral immunity. Following encounter with the activating Ag, mature B cells expand and initiate the primary Ab response that can be generally divided into short- and long-lived responses (1). In short-lived responses, B cell activation often occurs after exposure to a T cell-independent (TI) Ag that results in rapid terminal differentiation to predominantly low-affinity IgM-secreting PCs and limited IgG-secreting PCs. In contrast, long-lived responses are generated upon activation to T cell-dependent (TD) Ag that results in GC formation, where somatic hypermutation coupled with isotype switching occurs that engenders affinity-matured, Ag-specific B cells. These cells are subsequently selected based on improved Ab affinity toward Ag and those that are competitively successful are subject to terminal differentiation into PCs and memory B cells (B\(_{\text{mem}}\)). Long-lived PCs migrate to and persist in the bone marrow (BM) for decades and provide up to 80% of protective Ab titers to viral pathogens (2, 3).

As post-GC B cells commit to a PC fate, transforming events can occur that result in PC malignancies such as multiple myeloma (MM) and are characterized by the accumulation of clonotypic neoplastic Ab-secreting cells within lymphoid organs (4). Translocations that involve the Ig H chain are often present in PC neoplasms with the incidence increasing with the stage of tumorigenesis. It is estimated that up to 90% of advanced MM tumors involve the IgH locus (5–7). During the pathogenesis of PC neoplasms, translocations that juxtapose an oncogene and one of the Ig enhancers are common. Deregulation of the Myc (c-Myc) oncogene occurs in several B cell malignancies, including human MM and murine plasmacytoma. Studies using fluorescence in situ hybridization analysis show that ~88% of human MM cell lines and 45% of advanced primary MM tumors have karyotypic abnormalities that juxtapose Myc and an Ig enhancer (8). The most common translocation in murine plasmacytomas is t(12;15), which juxtaposes Myc to the distal IgH C\(\alpha\) gene (9–11), and is the direct counterpart of the t(8;14)(q24;q32) translocation observed in human Burkitt’s lymphoma (BL). Of the numerous outstanding questions concerning this translocation, a long established but still puzzling observation is that the clinical subtype of BL and murine PC neoplasms is tightly associated with the fine structure of translocation. For example, in the case of endemic BL, the translocation breakpoints in IG\(\text{H}\) always occur $5’$ of E\(_\mu\), resulting in a rearrangement in which Myc expression can be driven by the cooperative actions of the intronic IG\(\text{H}\) enhancer E\(_\mu\) and the 3$’$ IG\(\text{H}\) enhancer E\(_\alpha\). In the case of sporadic BL, the translocation breakpoints in IG\(\text{H}\) invariably fall $3’$ of E\(_\mu\), leading to a molecular structure in which Myc can only be deregulated by E\(_\alpha\). Elucidating the biological cause of the differential enhancer availability in endemic and sporadic BL has been an important goal of modeling the t(8;14)(q24;q32) translocation in transgenic mice. However, previous attempts to that end have been largely unsuccessful (12–18).

To create an experimental system in which the transformation-inducing potential of endemic vs sporadic BL translocations can be compared directly, a gene-insertion strategy was used to generate...
c-Myc-transgenic mice where Myc cDNA was inserted into the Cα gene that models the endemic BL translocation and transgenic strains where Eμ was deleted during gene targeting, thus creating a model of the sporadic BL translocation (19). Furthermore, gene insertion of Myc into the Cα gene recapitulates the t(12;15) translocation most common to murine plasmacytomas (20), which allows Myc to interact with downstream IgH enhancers, including Eμ, which is critical for Myc deregulation in PC tumors (18). Thus, the Cα-Myc-transgenic mice have great relevance to studying the origin of endemic BL and plasmacytomas, yet these transgenic mice exhibit little to no tumorigenesis. Only when deregulated Cα-Myc is combined with enforced expression of the anti-apoptotic Bcl-xL gene does fulminate PC transformation occur that reflects many features of human MM (20).

Despite its normal function in controlling cell proliferation (21, 22), c-Myc activation can lead to apoptosis under certain cellular stress (23). What determines c-Myc-induced proliferation vs apoptosis is hypothesized to depend on whether sufficient amounts of survival factors are available to prevent death. The failure to obtain sustainable levels of support for growth would lead to the elimination of overproliferating cells, thus providing a safeguard against uncontrolled oncogene-induced proliferation. Thus, heightened levels of c-Myc expression may limit cellular growth by increasing the threshold of survival factor signaling needed to maintain longevity. One such factor that is critical for normal PC survival is the interaction of B cell-activating factor belonging to the TNF family (BAFF) with its PC-expressed receptor B cell maturation Ag (BCMA) (24). Furthermore, several reports have shown that members of the BAFF family are aberrantly expressed in human MM (25). BAFF is resistant to BAFF-mediated survival. PCpre survived normally when targeted with 100 μg i.p. of either (4-hydroxy-3-nitrophenyl)acetyl (NP30)-keyhole limpet hemocyanin (KLH) emulsified in CFA or aluminum potassium sulfate (alum), or phosphoryl choline (PhC3-0VA) CFA (Biosearch Technologies). As indicated, some mice also received 200 μg of soluble recombinant BAFF (24) i.p. injections administered twice weekly. To examine TI responses, mice were challenged i.p. with 25 μg of NP30-Ficol suspended in balanced salt solution (BSS). After days noted, the animals were euthanized and spleen or BM cells were isolated. For secondary TD responses, 42-day primary NP-KLH CFA-immune animals were immunized i.p. with 50 μg of NP-KLH in alum followed by analyses 5 days thereafter.

In vitro LPS/anti-CD40 stimulation

Cells were cultured for 1–5 days in complete RPMI 1640 supplemented with 10% FBS containing IL-4 with or without 40 μg/ml LPS or 10 μg/ml agonistic anti-CD40 mAb FGK115. At the end of the culture, cells were harvested and either enumerated for PCs by ELISPOT or stained for FACS. As indicated, some cells were cultured in the presence of the caspase 3 inhibitor benzoylcarboxyl-Val-Ala-Asp(OMe)-fluoromethylketone ZVAD (MP Biomedicals) at a final concentration of 20 μM.

Flow cytometry

Cells were washed and resuspended in 5% bovine calf serum in BSS and stained with a mixture of mAbs, as noted, for the detection of multiple cell surface and intracellular Ags. Transgenic c-Myc protein levels were assessed by intracellular staining of 6-His using an anti-His fluorescent mAb (Miltenyi Biotec) combined with surface B220 and CD138 mAb labeling. For studies that examined NP-ε Cell subsets, cells were resuspended in pH 4.0 acetate buffer containing 0.05 M sodium acetate, 0.085 M NaCl, 0.005 M KCl, and 2% FBS in dH2O. Samples were incubated on ice for 1 min, followed by the addition of an equal volume of 0.1 M Tris buffer (pH 8.0) containing 2% FBS, washed, and stained. Purified rat IgG was used as an isotype control. For all studies, nonspecific staining was reduced by the addition of rat serum Ig and the FcR-blocking mAb 2.4G2. Stained cells were incubated for 30 min at 4°C followed by washing in bovine calf serum/BSS. Incubation with streptavidin-PE-cyanin 5.5 was performed for an additional 30 min at 4°C followed by washing. 4”,6-diamidino-2-phenylindole (DAPI) was added to cells at a concentration of 5 μM/ml to discriminate live vs dead cells. After surface staining, samples requiring intracellular staining were stained for histidine (Miltenyi Biotec), caspase 3, cytoplasmic IgM, or IgG using the Cytofix/Cytoperm reagent (BD Biosciences) according to the manufacturer’s instructions. Following staining, cells were washed with BD Permwash and 40 nM of the fluorescent DNA intercalating dye 7-aminoactinomycin D (7-AAD) was added 5 min before analysis.
Cell acquisition was performed with a DakoCytoMation CyAN ADP LX, where a minimum of 300,000 events was collected. Spectral overlap compensation and data analysis were performed using FlowJo software (Tree Star). Profiles are presented as 5% probability contours including outliers with gating based on fluorescence-minus-one and isotype controls. Cell and nuclear morphology of apoptotic cells, as measured by 7-AAD staining of fragmented irregular-shaped nuclei, was performed using the ImageStream 100 cytometer (Amnis) as previously described (35). Briefly, the instrument uses hydrodynamic focusing of cells in a core stream and illuminates cells in flow for fluorescence, dark field, and bright field image detection. All light is collected and separated by wavelengths bands using a spectral decomposition optical system, resulting in six subimages being collected for each cell based on spectral properties of bright field, dark field, and four fluorescences. Images of 10,000 cells per sample were analyzed using the IDEAS version 3.0 image analysis software (Amnis). Using the brightfield intensity gradient feature that determines image sharpness, images that are considered out of focus are excluded. Spectral overlap among the four fluorescences is removed by creating a compensation matrix using single-color fluorescent control samples that are collected on the instrument without bright field illumination. A matrix coefficient intensity plot is generated for each fluorescence, applied, and validated using control images. After compensation, images of in-focus single cells were selected on the basis of small bright field area, high bright field aspect ratio, and high nuclear contrast.

RT-PCR
After 48 h, in vitro-stimulated cells were harvested and total RNA was isolated using the RNeasy System (Qiagen). cDNA synthesis was performed using the Superscript II System (Life Technologies). PCR amplification was conducted by titrating cDNA samples with Taq polymerase (Boehringer Mannheim) and the primers for HPRT to normalize levels of template. Amplification of experimental transcripts was performed using normalized amounts of cDNA. The primers used were as follows: HPRT, Blimp-1, activation-induced cytidine deaminase (AID), germline IgM, germline IgG1, and postswitch IgG1 (36). Conditions used for amplification were 94°C, 55°C/62°C, and 72°C for 35 cycles. For real-time RT-PCR, PCRs were carried out using the iCycler IV (Bio-Rad) thermal cycler using the SYBR Green PCR Core Kit (Applied Biosystems) on an iCycler iQ instrument (Bio-Rad). Amplification conditions were 95°C for 8 min, followed by 40 cycles of 94°C for 15 s, 63°C for 45 s, and 72°C for 15 s. Primers used were as follows: Bcl-2: forward, 5′-CTG AAACATGCTCCTGGG-3′ and reverse, 5′-GGATGTGCTTTAGGCAATT-3′; Mcl-1: forward, 5′-TGGTTGACCAACTGACGAGAT-3′ and reverse, 5′-CCCAGTTGTGGTACGCTAT-3′; and Bax: forward, 5′-TCCCCAGATGAGTAAACTGGA-3′ and reverse, 5′-TGCGA TCCGACTCACAAT-3′. The relative level of expression for each primer target was calculated by the formula 2-ΔΔCT × 10000, where ∆ΔCT = (CT gene of interest − CT HPRT in experimental sample) − (CT gene of interest − CT HPRT in a no-template control sample), and CT is cycle threshold. RT-PCR was performed to distinguish wild-type vs transgenic c-Myc by using a common 5′ primer (5′-TCTCCA CTCACC AGCACA AC-3′) and 3′ primers specific for MycE+ (5′-ATG GTG ATG GTG ATG ATC-3′) and wild-type Myc (5′-CCT CGA GTT TCA GTT TA-3′). Conditions used for amplification were 95°C, 62°C, and 72°C for 20 cycles.

Immunoblot
After 48 h, in vitro-stimulated cells were harvested and CD138+ cells were purified using magnetic bead selection (Miltenyi Biotec). Protein samples were purified using magnetic bead selection (Miltenyi Biotec). Protein samples were transferred to nitrocellulose and membranes were blocked with 1% BSA and/or 5% milk in TBS with 0.05% Tween 20. Primary Ab incubations were done overnight at 4°C in blocking buffers that were recom- mended by the Ab suppliers (Bcl-2 clone 50E3 and Bcl-xL clone 54H6; Cell Signaling Technologies and Mcl-1; Rockland). After washing, secondary Ab incubations were done over 45-min periods in the same blocking buffers using Alexa Fluor 680-conjugated rabbit IgG (H + L; Molecular Probes). Blots were quantified using the Odyssey Infrared Imaging System (Li-Cor Biosciences).

ELISPOT
Spleen and BM Ab-secreting cells were quantified by a total Ig and Ag-specific Ig ELISPOT assay as previously described (37). Briefly, isolated cells were depleted of RBCs by ammonium chloride-Tris lysis, resuspended in complete RPMI 1640, and incubated for 5 h on Multiscreen 96-well plates (Millipore) precoated with either NP3 or NPα Ag or unlabeled anti-mouse IgM and IgG. Three-fold serial dilutions of cells were made with a start concentration of 150,000 cells/well. After incubation, plates were washed in 0.05% Tween 20 and incubated with secondary HRP-conjugated Ab to detect mouse IgM and IgG (Southern Biotechnol- ogy Associates). ELISPOT assays were developed by FAST 5-bromo-4chloro-3-indolyl phosphate/NBT chromogen substrate (Sigma-Aldrich). The number of Ab-secreting spots was quantified by direct visual counting using a dual-axis light dissecting microscope.

Results
PC development is impaired in transgenic c-Myc mice
To determine whether deregulation of c-Myc affected Ag-specific humoral immune responses, we assessed the development of NP-specific PCs in spleen and BM of mice that were immunized with the TD Ag NP-KLH. Results from ELISPOT assays, which quantify the frequency of PCs based upon Ab secretion, showed that immune nontransgenic littermates (control) developed high numbers of spleen anti-NP IgM PCs by day 3 after challenge and diminished to naive levels after 50 days (Fig. 1A, middle column). Coinciding with the decline in spleen IgM PCs, anti-NP PCs that had class switched to produce IgG were measured by day 7 after challenge and significantly decreased in number after 50 days. From day 14 postimmunization onward, the majority of anti-NP IgG PCs were of high affinity as measured by Ab binding to a low hapten ratio (NP3), indicating that affinity maturation had occurred. The reduction in spleen NP-specific IgM and IgG PCs by day 14 illustrates the short-lived nature of most of the splenic PCs quantified. Because it is known that long-lived PCs originate in the spleen, but subsequently migrate to the BM where they persist for weeks to months (38, 39), anti-NP IgG PCs within the BM of immune mice were also quantified. High numbers of anti-NP IgG PCs, the majority being high affinity, were observed by day 50 after challenge (Fig. 1B). Comparison of total IgM and IgG PCs from spleen and BM of immune control animals showed a similar pattern relative to naive groups. In contrast, approximately one half the number of spleen anti-NP IgM PCs was found in immune transgenic c-Myc heterozygous (c-Myc+/−) mice that decreased to naive levels by day 14 after challenge, and a small yet detectable number of IgG-producing PCs were measured after 14 days. Decreased numbers of splenic IgG PCs did not result from increased migration to BM, since very few NP-specific as well as total IgG PCs were found in BM of immune c-Myc+/− mice. More strikingly was the complete absence of NP-specific IgM and IgG PCs in spleen and BM of immune transgenic c-Myc homozy- gous (c-Myc+/+) mice. Thus, enforced expression of c-Myc dramatically inhibits the development of NP-specific PC differentiation. These results correlate with higher transgenic c-Myc protein expression in PCs compared with naive B cells in c-Myc−/− and c-Myc+/− mice (Fig. 2). However, PCs from c-Myc−/− mice expressed comparable c-Myc protein levels to B cells from c-Myc−/− mice, suggesting that high levels of c-Myc is not generally toxic to peripheral B cells. We further examined the frequency and tissue distribution of B cell subsets of transgenic c-Myc and control mice. Using a previously established flow cytometric strategy (40–42), three transitional B cell subsets, T1, T2, and T3, in addition to follicular (FO) and marginal zone (MZ) B cells can be identified in spleen based on expression of B220, AA4.1, IgM, CD23, and CD21. The number of FO B cells was slightly decreased in spleens from c-Myc−/+ mice compared with controls (Fig. 3A). In contrast, we did not find decreased numbers of MZ, T1, T2, and T3 B cells, suggesting that transgenic c-Myc expression may be important in the development or maintenance of FO B cells. The percentage of CDS+ peritoneal B cells was significantly increased in c-Myc−/+ animals (Fig. 3B). Further

The Journal of Immunology
7539

Downloaded from http://www.jimmunol.org/ by guest on April 14, 2017
analysis of B cell subsets in the peritoneal cavity demonstrated that the percentage of both the B220<sub>low</sub>CD19<sub>high</sub>CD5<sup>H11001</sup>B1a and B220<sub>low</sub>CD19<sub>high</sub>CD5<sup>H11002</sup>B1b B cells were increased in c-Myc<sup>H11001/H11001</sup>/mice compared with controls. Thus, c-Myc appears to be important for the development and/or maintenance of B1 B cells. Finally, B cell development was analyzed in BM from c-Myc<sup>H11001/H11001</sup>/ and control mice by flow cytometry (Fig. 3C). We detected a decrease in the number of pre-B cells, but no significant difference in the distribution of pro-B, immature, and mature B cells. The reduced number of pre-B cells suggests that increased c-Myc expression may inhibit their differentiation and/or maintenance.

To evaluate whether poor Ag-specific PC development in transgenic c-Myc mice was limited to either the TD Ag or adjuvant, mice were challenged with various combinations of Ag and adjuvant for 14 days, followed by spleen and BM ELISPOT assays (Fig. 4). Compared with mice immunized with NP-KLH emulsified in CFA, control animals that received NP-KLH precipitated in alum and PhC-OVA in CFA developed a weaker yet measurable IgG PC response. In contrast, significantly reduced numbers of Ag-specific PCs were measured in immune transgenic c-Myc animals. These data indicate that the impaired generation of Ag-specific PCs in c-Myc mice is independent of TD Ag and adjuvant.

Previous reports have demonstrated that the humoral immune responses to the TI and TD forms of the hapten NP are dramatically different. In contrast to TD forms, TI Ags such as NP-Ficoll primarily induce a rapid, local IgM response and to a lesser extent IgG (43, 44). To test whether c-Myc- transgenic B cells were impaired in their ability to generate PCs in the absence of T cell help, mice were immunized with NP-Ficoll for 7 days. Control animals showed a normal increase in spleen anti-NP IgM and IgG PCs, but c-Myc<sup>H11001/H11001</sup> and c-Myc<sup>H11001/H11002</sup> mice had a greatly diminished number of PCs (Fig. 5).

Therefore, although transgenic animals can generate Ag-specific PCs, enforced expression of c-Myc to the IgH C<sup>H9251</sup>/ locus significantly limits the magnitude of the Ag-specific PC response. This is regardless of the form of Ag, adjuvant, and short- or long-lived nature of PCs.

Transgenic c-Myc B cells undergo class switch recombination

The limited IgM- and IgG-secreting PCs in c-Myc mice could result from an inability of B cells to turn on the transcriptional machinery required for PC commitment and/or Ig class switch recombination. Thus, we examined whether transcription of the germline transcripts for IgM and IgG class-specific mRNAs was intact in transgenic c-Myc B cells. Splenic B cells from control and c-Myc animals were cultured in vitro with the polyclonal B cell stimuli, LPS, and agonistic anti-CD40 mAb. After 48 h, RNA was...
isolated from equivalent numbers of purified B cells. Using primers specific for CH genes, germline transcripts as well as postswitch transcripts, in which the I<sub>H</sub>/H9262 exon is spliced onto the 5'<sub>H</sub>/H11032 exon of another CH gene, were identified by RT-PCR (Fig. 6).

Transcription of germline IgM and IgG1 was intact in c-Myc B cells compared with control groups. In the presence of IL-4, a cofactor that promotes IgG class switching, both LPS and anti-CD40 successfully produced postswitch I<sub>H</sub>/H9262-C<sub>H</sub>/H9253 transcripts in all

FIGURE 3. c-Myc transgene expression results in fewer FO B cells, but increased numbers of B1 B cells. A, Freshly isolated splenocytes from control and c-Myc<sup>+/+</sup> mice were analyzed using a live cell gate to identify B220<sup>+</sup>/AA4.1<sup>+</sup> mature B cells and B220<sup>+</sup>/AA4.1<sup>+</sup> immature B cells. Immature B cells can be further segregated into IgM<sup>+</sup>/CD23<sup>-</sup> T1, IgM<sup>+</sup>/CD23<sup>-</sup> T2, and IgM<sup>+</sup>/CD23<sup>+</sup> T3 transitional B cell subsets. Mature B cells can be further segregated into CD21<sup>hi</sup>/CD23<sup>+</sup> MZ B cells and CD21<sup>lo</sup>/CD23<sup>+</sup> FO B cells. Additional gating on mature B cell subsets shows higher IgM surface expression on MZ B cells (gray histograms) relative to FO B cells (open histograms). Rat Ig staining for nonspecific binding is shown in black histograms. Numbers represent the percentage of total live lymphocytes in each gate or of cells in the gate indicated in parentheses above the plots. Absolute mean number ± SEM of each splenic B cell subset was calculated by multiplying the percentage of total live cells times total cells harvested from spleen of six mice. B, Peritoneal cells were analyzed to identify B220<sup>+</sup>/CD19<sup>+</sup> B2 cells or B220<sup>+</sup>/CD19<sup>+</sup> B1 cells. B1a cells are CD5<sup>+</sup> while B1b cells are CD5<sup>lo</sup>/CD19<sup>+</sup>. Numbers represent the percentage of total live lymphocytes in each gate or of cells in the gate indicated in parentheses above the plots. Absolute numbers of B1a, B1b, and B2 B cells were calculated from the same six mice as described in A. C, BM cells were analyzed to identify B220<sup>+</sup>/IgM<sup>+</sup> pro/pre-B cells, B220<sup>+</sup>/IgM<sup>+</sup> immature B cells, and B220<sup>+</sup>/IgM<sup>+</sup> mature B cells. Pro-B cells are CD43<sup>+</sup> while pre-B cells are CD43<sup>lo</sup>/IgM<sup>-</sup>. Numbers are the percentage of total BM cells in each gate or of cells in the gate indicated in parentheses above the plots. Absolute numbers of BM B cell subsets were calculated as described in A.

FIGURE 4. Transgenic c-Myc mice have defective development of Ag-specific PCs regardless of TD Ag and adjuvant. Spleen and BM cells were prepared from mice immunized for 14 days with the indicated TD Ag and adjuvant. NP<sub>30</sub>- or PC<sub>30</sub>-specific IgG-secreting PCs were quantified by ELISPOT. Results are expressed as the mean ± SEM for six mice per group.
B cells. Furthermore, activation of the transcriptional repressor Blimp-1, which is required for PC differentiation (47, 48), and AID, which is critical for class-switching and somatic hypermutation (49), were equivalent between transgenic c-Myc and control groups. Together, these data indicated that the attenuation of PC development in transgenic c-Myc mice was not due to an inability to activate transcription factors that drive class switching and the terminal differentiation of B cells.

Transgenic c-Myc mice have defective Ag-specific PCs and early Bmem despite intact GC responses

To investigate the mechanism responsible for decreased numbers of persisting PCs in c-Myc mice, the expansion and differentiation of Ag-activated B cells into NP-specific subsets were measured following immunization with NP-KLH in CFA. Using a previously established six-color flow cytometric strategy that combines fluorescent-labeled Ag binding with cell surface phenotype (47, 50), NP-specific GC B cells, PCs, and their immediate precursors and Bmem can be identified. To avoid possible cytophilic Ig binding to cells that would erroneously appear as NP+, cells from mice were acid treated to remove any nonmembrane-expressed Ab (51).

Staining of spleen B cells with a rat IgG isotype control demonstrated <0.01% nonspecific binding (Fig. 7A, first column). Spleen cells from mice that received adjuvant alone (naïve) also demonstrated negligible frequencies of NP+ B cells (Fig. 7A, second column). Fourteen days following challenge, the frequency of NP IgDlo B cells in spleens of immune control animals significantly expanded to 0.7 ± 0.2% of total live cells (Fig. 7A, third column). In contrast, the percent NP IgDlo B cells was reduced ∼1.4-fold in c-Myc+/− mice and 7-fold in c-Myc+/- mice relative to control mice. To determine whether the decreased frequencies of NP+ IgDlo B cells in immune c-Myc animals segregated with a particular subset, the NP IgDlo B cell population was gated upon and the expression of CD138 and B220 was examined. This strategy identifies Ag-specific GC B cells (B220+CD138−GL7+), Bmem (B220+CD138+CD79b−), and PCs and their precursors (B220lowCD138−). In control mice, all three NP+ B cell subsets were distinguished (Fig. 7A, fourth column). Expression of the GC marker GL7 (52, 53) further confirmed that NP-specific B cells within the B220+CD138− subset of immune control animals were undergoing a GC response (Fig. 7A, fifth column). In contrast, immune c-Myc transgenic animals generated reduced numbers of NP-specific CD138− B220low PCs and CD138− B220− Bmem with the majority of NP+ B cells comprising the CD138− B220− subset that contained GL7+ GC B cells. Absolute numbers of each NP+ B cell subset were quantified and are proportional to the frequencies measured by FACS (Fig. 7B). Thus, upon enforced c-Myc expression, a deficiency of Ag-specific B cells terminally differentiating to long-lived PCs does not result from impaired GC B cell responses. These findings also suggest that c-Myc expression diminishes the development of Bmem, which is further evidenced by a significant decrease in the frequency of NP IgDloCD138− B220− B cells in the BM of immune c-Myc+/− and c-Myc+/- mice relative to control animals (Fig. 7, C and D) where memory can persist (47).

Enforced c-Myc expression impairs Bmem responses

Bmem function to support the long-lived BM PC pool by providing the host with a rapid burst of Ag-specific PCs at a pace and quality manifold greater than that observed during the primary encounter with Ag (54). Because the signals that control PC differentiation and survival from post-GC B cells vs Bmem may differ, we determined the functional impact of c-Myc on Bmem during a secondary challenge. Mice were immunized with NP-KLH in CFA for 42 days, followed by secondary challenge to NP-KLH in alum for an additional 5 days (Fig. 8A, denoted by day 47). Recall responses were compared with baseline levels of NP-specific spleen B cells in mice that received adjuvant alone (naïve), mice that were immunized with NP-KLH CFA for 42 days only (day 42), and in mice that received NP-KLH alum only for 5 days (day 5). NP+ B cells were absent in naïve animals (Fig. 8A, first column), expanded to 1.6 ± 0.1% on day 42 before rechallenge in control animals (Fig. 8A, second column), but were virtually absent in c-Myc mice. Persisting NP+ B cells in day 42 control mice contained Bmem since 5 days after secondary challenge, both the percentage (Fig. 8A, fourth and fifth columns) and absolute number of NP+ B cells (Fig. 8C) showed a significant expansion with 80% representing the CD138− B220− Bmem compartment. This is further supported by the unimodal up-regulated expression of the Igβ BCR coreceptor CD79b (Fig. 8A, sixth column) previously demonstrated to be expressed by this Bmem population (47, 50). In contrast, both the percentage and number of total NP+ B cells as well as CD138− B220− cells were reduced in c-Myc transgenic mice following secondary challenge. Furthermore, NP IgDlo CD138− B220− Bmem within the spleen of day 47 c-Myc+/- mice
from apoptosis and is restricted to mature PCs, but not PCpre. Impaired PC development in transgenic c-Myc mice results in diminished the long-term survival of these effector cell populations. These results are consistent with a graded decrease in Bmem. Thus, approximately a 2- and 8-fold reduction in anti-NP IgG PC numbers. NP-specific IgDlow gated B220+ cells, of which the majority were high IgDlow gated IgDlow B cells from immune BM of mice in A, C. The expression of CD138 and B220 of NP IgDlow gated cells is shown in the light gray histograms. B, Total numbers were calculated for the indicated NP-specific cell population from immune animals shown in A, C. The frequency of NP-specific IgDlow B cells was determined from DAPI CD4+ CD8- gated BM cells of 14-day NP-immune mice shown in A. Rat Ig isotype controls for nonspecific binding are shown in the first column. The expression of CD138 and B220 of NP IgDlow gated cells is shown in the third column. D, Total NP IgDlow B cells from immune BM of mice in C are shown. Data represent one of three independent experiments.

FIGURE 7. Ag-specific PCs and early developing Bmem are impaired in c-Myc mice. A. The frequency of NP-specific IgDlow B cells was determined from DAPI CD4+ CD8- gated spleen cells of naive and 14-day NP-immune mice. Insets represent the region used for calculating mean ± SEM cell frequencies from four mice per group. Nonspecific binding of rat Ig is shown in the first column. The fourth column shows expression of CD138 and B220 on NP IgDlow gated cells, with the CD138 B220populations to include PCs and PCpre, the CD138 B220- population to include Bmem and the CD138 B220+ population to include GC B cells. Representative percentages of each population are shown. Expression of the GC marker GL7 on CD138 B220+ gated cells is shown in the fifth column and is represented by the open black-lined histograms. Rat Ig staining on CD138 B220+ cells is shown in the light gray histograms. B, Total numbers were calculated for the indicated NP-specific cell population from immune animals shown in A, C. The frequency of NP-specific IgDlow B cells was determined from DAPI CD4+ CD8- gated BM cells of 14-day NP-immune mice shown in A. Rat Ig isotype controls for nonspecific binding are shown in the first column. The expression of CD138 and B220 of NP IgDlow gated cells is shown in the third column. D, Total NP IgDlow B cells from immune BM of mice in C are shown. Data represent one of three independent experiments.

bimodally expressed CD79b, which was completely absent in the memory fraction of c-Myc+/+ animals (Fig. 8A, sixth column). Together, the nominal expansion of NP+ spleen B cells, the graded reduction in CD79b expression, and the significantly diminished numbers of total Bmem indicates that increasing levels of C-Myc expression impairs the persistence of Bmem. This is further supported by a graded reduction of NP+CD138 B220− Bmem in BM of c-Myc mice (Fig. 8, B and C).

The functional capacity of Ag-responding Bmem to generate PCs was investigated by performing ELISPOT analyses of spleen and BM cells from immunized mice (Fig. 8D). Control mice that received a secondary challenge generated high numbers of spleen and BM NP-specific IgG PCs, of which the majority were high affinity. In contrast, c-Myc+/+ and c-Myc−/− mice showed approximately a 2- and 8-fold reduction in anti-NP IgG PC numbers. These results are consistent with a graded decrease in Bmem. Thus, although c-Myc does not affect GC responses, affinity maturation, and commitment to PCs or Bmem increasing c-Myc levels severely diminished the long-term survival of these effector cell populations.

Impaired PC development in transgenic c-Myc mice results from apoptosis and is restricted to mature PCs, but not PCpre.

It has been previously shown that naive C-Myc-harboring B cells within spleen and lymph nodes have a 2- to 3-fold higher spontaneous proliferative rate and can undergo spontaneous apoptosis or upon in vitro LPS stimulation, compared with control B cells (20). The propensity of transgenic Myc B cells to undergo apoptosis in these studies did not distinguish whether dying B cells were directly linked to a specific activation state. Whether enforced c-Myc expression in B cells led to apoptosis in the context of terminal differentiation was investigated in vitro after stimulation with LPS and agonistic anti-CD40 mAb (Fig. 9A). Purified spleen B cells from control and transgenic c-Myc mice were cultured 48 h with stimuli, followed by FACS to measure apoptosis via intracellular caspase 3 activation in B cells (B220CD138−) and terminal differentiating PCs (B220+CD138−). Neither B cells nor PCs of control mice showed positive staining for the cleaved, active form of caspase 3 (Fig. 9, red histograms). Confirmation that caspase 3 staining was indeed at baseline levels was provided by staining of cells from parallel cultures that contained the caspase 3 inhibitor ZVAD (Fig. 9, light gray histograms). Cultured B cells from c-Myc mice also showed negative staining for caspase 3. In contrast, terminal differentiating CD138+ PCs from c-Myc+/+ and c-Myc−/− mice showed positive staining for caspase 3, indicating that a portion of PCs were undergoing apoptosis. This was abrogated with the addition of ZVAD. In vivo examination of NP-specific PCs and Bmem from day 7-challenged mice confirmed that both of these effector B cell populations were undergoing apoptosis in transgenic c-Myc mice (Fig. 9B). Together, these results indicate that c-Myc induces apoptosis of B cells terminally differentiating to a PC and Bmem fate.

To provide additional evidence that terminal differentiating B cells were selectively undergoing apoptosis, we used multispectral imaging flow cytometry, a novel technology that integrates cell
microscopy with flow cytometry in real time. This flow-imaging platform creates digital images of each cell as it passes through the detector, discriminating specific cell types within a heterogeneous population based on fluorescence combined with morphology. The application of this technology to measure apoptosis has been previously established (35, 55). In this study, we take advantage of this platform to determine whether apoptosis of terminally differentiating B cells is restricted to mature Ab-secreting CD138\(^+\) PCs, as measured by cytoplasmic Ig production, or their immediate precursors that do not secrete Ab yet also express CD138\(^+\).

Spleen cells from control and c-Myc\(^+-/\) mice were stimulated with LPS for 48 h, followed by staining for surface B220 and CD138 expression and intracellular Ig. The cationic nucleotide-binding dye 7-AAD was added to samples before analysis. Although 7-AAD binds to both necrotic and apoptotic cells, each type of dying cell is morphologically distinguishable. Necrotic cells harbor intact nuclei, whereas apoptotic cells have fragmented nuclei with condensed chromatin. Apoptotic cells were identified using two standard image-based features from the IDEAS software: the gray histograms represent CD79b expression on naive B cells. The frequency of NP-specific IgD\(^+\) B cells was determined from DAPI\(^+\) CD138\(^+\) CD79b\(^+\) B cells gated (Insets), and is represented by the black-lined histograms. The gray histograms represent CD79b expression on naive B cells. B. The frequency of NP-specific IgD\(^+\) B cells was determined from DAPI\(^+\) CD138\(^+\) CD79b\(^+\) gated BM cells of mice shown in A, C. Total numbers were calculated for the indicated NP-specific cell population from spleen (left column) and BM (right column) of immune animals shown in A, D. Spleen and BM cells were prepared from mice examined in A–C. The numbers of PCs secreting high-affinity NP-specific (NP\(_{10}\) binding) IgG relative to total NP-specific (NP\(_{30}\) binding) IgG were quantified by ELISPOT. Data are expressed as the mean \(\pm\) SEM for eight mice per group.

FIGURE 8. Transgenic heterozygous and homozygous c-Myc mice show a graded defect in the expansion and differentiation of NP-specific B\(_{\text{mem}}\), upon secondary Ag exposure. A. The frequency of NP\(^+\)IgD\(^{\text{low}}\) B cells was determined from DAPI\(^+\) CD4\(^+\) CD8\(^-\) gated spleen cells of mice administered adjuvant only (naive), mice that received a primary challenge for 42 days (day 42), mice that received only the secondary challenge over 5 days (day 5), and from 42-day NP-immune animals that received a secondary NP-KLH challenge for an additional 5 days (day 47). Insets represent the region used for calculating mean \(\pm\) SEM cell frequencies from four mice per group. The fifth column shows expression of CD138 and B220 on NP\(^+\) IgD\(^{\text{low}}\) gated cells as described in Fig. 5. Expression of the B\(_{\text{mem}}\) marker CD79b on the CD138\(^+\) B220\(^+\) B\(_{\text{mem}}\) population is shown in the sixth column and is represented by the black-lined histograms. The gray histograms represent CD79b expression on naive B cells. B. The frequency of NP-specific IgD\(^+\) B cells was determined from DAPI\(^+\) CD4\(^+\) CD8\(^-\) gated BM cells of mice shown in A, C. Total numbers were calculated for the indicated NP-specific cell population from spleen (left column) and BM (right column) of immune animals shown in A, D. Spleen and BM cells were prepared from mice examined in A–C. The numbers of PCs secreting high-affinity NP-specific (NP\(_{10}\) binding) IgG relative to total NP-specific (NP\(_{30}\) binding) IgG were quantified by ELISPOT. Data are expressed as the mean \(\pm\) SEM for eight mice per group.

We have previously demonstrated that normal long-lived BM PCs express heightened levels of the BCMA receptor, but not transmembrane activator and calcium-modulator and cytoplitin ligand interactor (TACI) or BAFF-R relative to mature naive B cells (24). Furthermore, the interaction between BCMA and BAFF or APRIL is critical for long-term PC survival since BCMA\(^--\) mice sustain significantly reduced numbers of BM PCs compared with wild-type control animals. We therefore asked whether BAFF could mediate survival of transgenic c-Myc PCs. To this end, the surface expression of the BAFF receptors TACI, BCMA, and BAFF-R on Ag-responding B cell subsets was examined (Fig. 11A). Because...
so few PCs were found in the BM of c-Myc animals (Fig. 1B), we chose to examine mature B cells, GC B cells, PCpre, and PCs from spleen of mice 14 days after NP-KLH immunization. We and others have previously demonstrated that 2 wk following immunization is sufficient time for the spleen to generate post-GC PCs destined to become long-lived (38, 56). No significant differences in BAFF-R expression levels were observed in the various B cell subsets among the mice. BCMA was expressed at slightly higher levels on GC B cells and PCpre from c-Myc animals, but was up-regulated on PCs at levels equivalent to control PCs. In contrast, TACI expression levels were significantly up-regulated on PCs from c-Myc animals compared with control PCs.

Genetic studies in mice have demonstrated TACI to negatively regulate B cell proliferation, Ig secretion, and survival (57–59), and under certain conditions direct engagement of TACI using agonistic mAbs results in apoptosis (57, 59). To determine whether high TACI expression on c-Myc PCs influenced apoptosis, ex vivo PCs and those generated in vitro upon LPS stimulation were cultured 48 h with graded doses of recombinant BAFF and APRIL ligand or agonistic anti-TACI mAb. Results demonstrated that there was no difference in the percentage of caspase 3-positive PCs from cultures containing ligand and anti-TACI mAb compared with control groups (data not shown). These findings implied that within the context of c-Myc-induced apoptosis of PCs, signaling through TACI did not initiate death. An alternative hypothesis is that heightened TACI expression on c-Myc PCs increased the threshold for BAFF signaling required for their continued survival. To test this possibility, mice were challenged with NP-KLH and administered exogenous BAFF twice weekly for 2 wk. The absolute numbers of spleen PCs and PCpre were quantified after 14 days (Fig. 11B). Results demonstrated that increasing BAFF levels did not improve the persistence of mature PCs beyond numbers observed in mice expressing endogenous BAFF only. Consistent with the aforementioned in vitro studies, these findings indicate that BCMA/TACI-BAFF interactions fail to support survival in c-Myc-harboring PCs. In contrast, heightened levels of BAFF resulted in a 3-fold greater number of PCpre in c-Myc mice, indicating that exogenous BAFF was biologically active in vivo and that PCpre but not end-stage PCs are sensitive to BAFF-mediated growth and/or survival.

FIGURE 9. B cells differentiating to a PC fate undergo apoptosis in transgenic c-Myc mice. A, Spleen cells prepared from the indicated mice were depleted of T cells and cultured in vitro with IL-4 and either LPS or agonistic anti-CD40 mAb for 48 h. Cells were collected and apoptosis was measured by intracellular caspase 3 staining of B cells (B220<sup>−</sup>CD138<sup>+</sup>) and PCs (B220<sup>jw</sup>CD138<sup>+</sup>) by multicolor FACS. Caspase 3 staining of cells cultured with stimuli is represented by the red histograms. As a specificity control, stimulated cells were also cultured in the presence of the caspase 3 inhibitor ZVAD throughout the 48 h and subjected to caspase 3 staining as shown by the light gray histograms. Nonspecific intracellular binding of rat Ig is represented by the open black-lined histograms. Results are representative of four independent experiments. B, Apoptosis of spleen NP<sup>+</sup> (DAPI/CD4<sup>+</sup>CD8<sup>+</sup>NP<sup>+</sup>IgD<sup>low</sup> gated) PCs and early Bmem from 7-day NP-immune mice was measured by caspase 3 staining as shown by the red histograms. An irrelevant isotype control is represented by the open black-lined histograms. Data shown are representative of six mice per group.

FIGURE 10. c-Myc-induced apoptosis of terminally differentiating B cells is restricted to mature Ab-secreting PCs. A, Spleen cells from control and c-Myc<sup>+/−</sup> mice were depleted of T cells and cultured in vitro with LPS for 48 h. Cells were then collected and surface labeled for expression of B220 and CD138, followed by intracellular staining for Ig. 7-AAD was added to samples immediately before data acquisition on the ImageStream100 cytometer. Bright field (white), B220 (magenta), IgM and IgG (green), CD138 (yellow), and 7-AAD (red) composite images for three representative cells are shown for B220<sup>low</sup>/intracellular Ig<sup>+</sup>CD138<sup>+</sup>/7-AAD end-stage PCs, B220<sup>+</sup>intracellular Ig<sup>+</sup>/CD138<sup>+</sup>/7-AAD PCpre, and B220<sup>+</sup>intracellular Ig<sup>+</sup>CD138<sup>+</sup> B cells. B, The percentage of apoptotic PCs, PCpre, and B cells were quantified using two standard image-based software analysis features: Area and Spot Small Total. Data shown are based on these algorithms calculated from 10,000 images/group and are representative of three independent experiments.
Studies in both human and mouse PC malignancies have demonstrated that up-regulation of antiapoptotic genes of the Bcl-2 family contributes to tumor survival. In human MM, increased expression of Bcl-xL and Mcl-1 control survival (60–62), whereas mouse plasmacytomas and healthy PCs appear to rely more on Bcl-xL and Bcl-2 for their survival (63–65). To determine whether enforced c-Myc expression altered expression of Bcl-2 family members, in vitro-generated control and c-Myc spleen CD138+/H11001 PCs were purified and transcription of Bcl-2, Mcl-1, and Bcl-xL were tested by real-time PCR (Fig. 11C). Results demonstrated that expression of these genes was equivalent, if not higher, in c-Myc-harboring PCs compared with control PCs generated in response to LPS plus IL-4. This indicates that c-Myc-induced apoptosis of PCs does not result from an inability to transcribe these genes. Of interest, however, is that in contrast to control PCs, the survival factors IL-6 and BAFF significantly diminished the expression of all three genes in c-Myc PCs. Further examination at the protein level demonstrated that Mcl-1, Bcl-2, and Bcl-xL expression levels increased in control PCs with IL-6 and BAFF. PCs from c-Myc+/+ mice had a similar pattern of Mcl-1 and Bcl-2 protein expression in response to IL-6 and BAFF. In contrast, basal levels of Bcl-xL protein expression was low in c-Myc+/+ PCs and was not significantly increased after IL-6 and BAFF stimulation. These findings suggest that although targeted expression of c-Myc to the IgH Cα locus prevents BAFF-induced expression of antiapoptotic genes in mature PCs, c-Myc impairs PC survival by inhibiting Bcl-xL protein expression.

Because Bcl-xL plays a critical role in the survival of human and mouse PC malignancies, we crossed single transgenic c-Myc mice with mice that express constitutive Bcl-xL within the B cell compartment to test whether enforced expression of this Bcl-2 family member might permit PC sensitivity to IL-6 and BAFF, thus restoring survival. It has been previously demonstrated that Myc/Bcl-xL double-transgenic mice spontaneously generate PCs and develop PC tumors that mimic human MM (20). Spleen cells containing spontaneous-developing PCs were prepared from c-Myc−/−Bcl-xL−/− mice and cultured in vitro for 5 days with the indicated stimuli. BM cells from 42-day NP-immune control mice were cultured in the same manner as a source of normal long-lived PCs. The survival of total IgG-secreting PCs was quantified by ELISPOT. Data are expressed as the mean ± SEM for three independent experiments.

FIGURE 11. PCs from transgenic c-Myc mice fail to respond to BAFF-mediated survival. A, Expression of the BAFF receptors TACI, BCMA, and BAFF-R on the indicated population is shown from spleen cells of 14-day NP-immune mice. Receptor expression levels on gated cells are represented by the black-lined histograms for control mice, red-lined histograms for c-Myc−/− mice, and blue-lined histograms for c-Myc+/+ mice. The gray histograms in the first column represent nonspecific rat Ig staining. Data are representative of eight mice per group. B, Mice were immunized with NP-KLH and administered BAFF i.p. twice weekly for 2 wk. Total numbers of spleen PC and PCs were quantified on day 14, based on their respective phenotype. Results are expressed as the mean ± SEM for eight mice per group. C, Spleen B cells from control and c-Myc+/+ mice were cultured in vitro for 48 h with LPS plus IL-4 with or without IL-6 or BAFF. Cells were then collected and RNA was isolated from purified CD138+ PCs. Real-time PCR analysis was performed and the relative expression of antiapoptotic genes was determined compared with HPRT. Protein levels of each gene were determined from CD138+ PCs by Western blot analysis. Densitometry values of protein expression relative to GAPDH are shown. D, BM cells containing spontaneous-developing PCs were prepared from c-Myc−/−Bcl-xL−/− mice and cultured in vitro for 5 days with the indicated stimuli. BM cells from 42-day NP-immune control mice were cultured in the same manner as a source of normal long-lived PCs. The survival of total IgG-secreting PCs was quantified by ELISPOT. Data are expressed as the mean ± SEM for three independent experiments.
the combination of the two stimuli significantly increased the survival of control PCs. Survival of PCs from double-transgenic mice was supported by IL-6, but was dramatically increased with the addition of BAFF. These data indicate that although enforced expression of Bcl-x\(_L\) promotes neoplastic transformation of c-Myc-harboring PCs, these mature Ab-secreting cells evade death by now being responsive to BAFF.

**Discussion**

Deregulation of c-Myc is tightly associated with many B cell neoplasms, including those that involve the transformation of terminally differentiated PCs. Yet, how c-Myc controls the differentiation fate of post-GC B cells resulting in a tumor-initiating effector cell is unknown. In this study, we have demonstrated that targeting Myc to the *Igh* Ca locus controls the development of short- and long-lived effector cells. The findings establish that enforced c-Myc expression dramatically impairs the primary Ab response to TI and TD Ags, as measured by reduced numbers of PCs (Figs. 1 and 5). These data indicated that regardless of T cell help, there was an inherent defect in the magnitude of the short- and long-lived PC response. Reduced PC frequencies were not attributable to a particular Ag and/or adjuvant specificity (Fig. 4) and, furthermore, were not caused by an inability to form GC responses, class switch, or to turn on the transcriptional machinery required for PC commitment (Figs. 6 and 7). Thus, Ag-activated B cells harboring a T (12, 15) translocation where Myc is inserted into the Ca gene that preserves E\(_{\mu}\), E\(_{\alpha}\), and all other regulatory elements within the *Igh* locus progress normally through the molecular and cellular processes leading up to the final maturation of a PC. Further examination of PC viability revealed that c-Myc triggered apoptosis of PCs (Figs. 9 and 10), thus accounting for reduced PC numbers generated in vitro and in vivo. Of particular interest is that apoptosis mediated by c-Myc is specific to the final stage of PC maturation when Ab is secreted while PCpre that express membrane p18 is rarely seen in primary MM cells (83). We believe that the human MM cell lines (82), this might explain why a deletion of p18INK4c has previously been shown to bind to and negatively regulate CDK6 (78, 79), leading to the inhibition of phosphorylated Rb by CDK6 and cycle arrest in G1 (80). Importantly, p18INK4c is required for generating functional Ab-secreting PCs because a deficiency in this gene results in a profound decrease of Ag-specific primary and secondary Ab responses (81). Strikingly similar to our studies, p18INK4c-deficient B cells could commit to a PC fate, as demonstrated by their transcriptional profile, they failed to cycle arrest and consequently underwent apoptosis. These data indicate that withdrawal from cell cycle is necessary for PC survival. Therefore, enforced Myc expression likely disallows cycle arrest upon terminal differentiation and because of this opposing nature the mature PC is triggered to die. Results from preliminary studies to investigate cell cycle genes show that PCs isolated from c-Myc mice express dramatically reduced p18INK4c as well as p27Kip1, suggesting that enforced c-Myc expression may mimic the apoptosis of p18INK4c-deficient PCs. Although deletion of p18INK4c has been reported in human MM cell lines (82), this might explain why a deletion of p18 is rarely seen in primary MM cells (83). We believe that the reason PCpre are unaffected by Myc-induced death is due to their inherent proliferative nature, cells at this stage of terminal differentiation require constant cell cycle progression for both their self-renewal and further differentiation to Ab-secreting PCs (27). This is consistent with the finding that B1 B cells, also a self-renewing population, are increased in transgenic c-Myc mice (Fig. 3). Accumulation of additional survival advantage mutations would be required within the tumor-initiating PCpre compartment or upon final maturation to PCs for tumor progression.

Whether Myc induces apoptosis of Bmem and PCs via an imbalance in cell cycle regulation or simply by these cells having too much Myc that it triggers a stress response leading to death needs further study. But the fact that apoptotic pathways need to be disrupted by Myc to promote transformation tells us that a tumor-initiating cell can progress only so far before a survival checkpoint within the cell is breached and instructs it to die. This scenario is likely to occur as the tumor-initiating cell attempts to become a tumor-propagating type cell. The most direct connection of Myc and Bcl-2 family proteins has come from studies demonstrating that Myc suppresses Bcl-2 or Bcl-x\(_L\), particularly in precancerous B cells of E\(_{\mu}\)-Myc-transgenic mice, and therefore are more susceptible to death. Both of these antia apoptotic genes are normally induced by IL-6 to promote survival (84). Myc could in theory disrupt the IL-6 and/or other survival factor antia apoptotic signaling
pathways triggering cell death. Some evidence lending support to this hypothesis comes from our data showing that although both IL-6 and BAFF significantly increased Bcl-2, Mcl-1, and Bcl-xL expression in control PCs, these antiapoptotic genes were profoundly suppressed by IL-6 and BAFF in Myc-harboring PCs (Fig. 11C). Normal PCs are dependent on the BM microenvironment for survival, growth, and differentiation. These processes are, in part, mediated by paracrine IL-6 and BAFF. Our results indicate that these natural means for PC survival are themselves an essential checkpoint that, if disrupted by Myc, guards the cell from further transformation by dying but can be resurrected if this checkpoint is overridden by enforced Bcl-xL (Fig. 11D). This checkpoint appears to be selective to the final stage of PC differentiation, despite BCMA and high TACI receptor expression, since tumor-initiating Ppc not only persist in Myc-transgenic mice but proliferate favorably in response to BAFF (Fig. 11B). Furthermore, it is possible that c-Myc does not allow Bseen to be sustained by BAFF signaling either, but a recent report indicates that Bmem survival is independent of BAFF (85). Exactly why C-Myc Bseen are dying is an important question that will require more study.

In human primary MM cells and established cell lines, it has been shown that TACI expression is bimodal with TACIhigh MM cells resembling BM PCs and TACIlow MM cells resembling the characteristics of plasmablasts (86, 87). The gene expression signature of TACI-expressing MM cells suggests that TACIhigh tumors represent those that are dependent on the BM microenvironment for survival (86) and, furthermore, are growth arrested by the BAFF/APRIL inhibitor atacicept (88). These studies suggest that TACI expression may be a valuable predictive marker in identifying patients with plasmacytomas who are likely to respond favorably to atacicept. We suggest that high TACI expression may furthermore be a useful diagnostic indicator for more accurately predicting the risk of progression in patients who are asymptomatic, but harbor proliferating monoclonal PCs as in the monoclonal gammopathy of undetermined significance disorder. All in all, our findings point to the notion that Ppc is the target cell population for transformation and that an additional oncogenic event(s), which enables BAFF dependency for survival, must occur as they mature to functional Ab-secreting malignant PCs.

Acknowledgments
We thank Joanne Lannigan and Michael Solga of the University of Virginia Flow Cytometry Core for technical expert assistance. We thank Drs. Timothy Bender and Ulrike Lorenz for helpful discussions. We thank Dr. Brian P. O’Connor for assistance in preparing this manuscript.

Disclosures
The authors have no financial conflict of interest.

References


